294 related articles for article (PubMed ID: 36768484)
41. Mechanisms of secretion and spreading of pathological tau protein.
Brunello CA; Merezhko M; Uronen RL; Huttunen HJ
Cell Mol Life Sci; 2020 May; 77(9):1721-1744. PubMed ID: 31667556
[TBL] [Abstract][Full Text] [Related]
42. [Neuroprotective treatment of tauopathies].
Respondek G; Krey L; Huber M; Pflugrad H; Wegner F; Höglinger GU
Nervenarzt; 2021 Dec; 92(12):1227-1238. PubMed ID: 34652482
[TBL] [Abstract][Full Text] [Related]
43. Tau Lysine Pseudomethylation Regulates Microtubule Binding and Enhances Prion-like Tau Aggregation.
Xia Y; Bell BM; Giasson BI
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175990
[TBL] [Abstract][Full Text] [Related]
44. Disease-Associated Mutations in Tau Encode for Changes in Aggregate Structure Conformation.
Sun KT; Patel T; Kang SG; Yarahmady A; Srinivasan M; Julien O; Heras J; Mok SA
ACS Chem Neurosci; 2023 Dec; 14(24):4282-4297. PubMed ID: 38054595
[TBL] [Abstract][Full Text] [Related]
45. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
[TBL] [Abstract][Full Text] [Related]
46. The ordered assembly of tau is the gain-of-toxic function that causes human tauopathies.
Goedert M
Alzheimers Dement; 2016 Oct; 12(10):1040-1050. PubMed ID: 27686274
[TBL] [Abstract][Full Text] [Related]
47. Tau protein aggregation: Key features to improve drug discovery screening.
Giovannini J; Smeralda W; Jouanne M; Sopkova-de Oliveira Santos J; Catto M; Voisin-Chiret AS
Drug Discov Today; 2022 May; 27(5):1284-1297. PubMed ID: 35085785
[TBL] [Abstract][Full Text] [Related]
48. The Structure Biology of Tau and Clue for Aggregation Inhibitor Design.
Wang D; Huang X; Yan L; Zhou L; Yan C; Wu J; Su Z; Huang Y
Protein J; 2021 Oct; 40(5):656-668. PubMed ID: 34401998
[TBL] [Abstract][Full Text] [Related]
49. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies.
Ferreira A; Bigio EH
Mol Med; 2011; 17(7-8):676-85. PubMed ID: 21442128
[TBL] [Abstract][Full Text] [Related]
50. Aggregation, Transmission, and Toxicity of the Microtubule-Associated Protein Tau: A Complex Comprehension.
Hu J; Sha W; Yuan S; Wu J; Huang Y
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834471
[TBL] [Abstract][Full Text] [Related]
51. Potential mechanisms and implications for the formation of tau oligomeric strains.
Gerson JE; Mudher A; Kayed R
Crit Rev Biochem Mol Biol; 2016; 51(6):482-496. PubMed ID: 27650389
[TBL] [Abstract][Full Text] [Related]
52. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
[TBL] [Abstract][Full Text] [Related]
53. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
54. Modulating disease-relevant tau oligomeric strains by small molecules.
Lo Cascio F; Garcia S; Montalbano M; Puangmalai N; McAllen S; Pace A; Palumbo Piccionello A; Kayed R
J Biol Chem; 2020 Oct; 295(44):14807-14825. PubMed ID: 32737202
[TBL] [Abstract][Full Text] [Related]
55. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
56. Disentangling tau: One protein, many therapeutic approaches.
Lane-Donovan C; Boxer AL
Neurotherapeutics; 2024 Mar; 21(2):e00321. PubMed ID: 38278659
[TBL] [Abstract][Full Text] [Related]
57. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies.
Panza F; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Cirillo N; Damiani C; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Lozupone M
Expert Opin Investig Drugs; 2023; 32(7):625-634. PubMed ID: 37405389
[TBL] [Abstract][Full Text] [Related]
58. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR
J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057
[TBL] [Abstract][Full Text] [Related]
59. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
[TBL] [Abstract][Full Text] [Related]
60. Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity.
Frenkel-Pinter M; Tal S; Scherzer-Attali R; Abu-Hussien M; Alyagor I; Eisenbaum T; Gazit E; Segal D
Neurodegener Dis; 2017; 17(2-3):73-82. PubMed ID: 27760426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
